Dr. Ahmad Tarhini on Ipilimumab vs Interferon-α2b for Resected High-Risk Melanoma

June 12, 2019
Ahmad A. Tarhini, MD, PhD
Ahmad A. Tarhini, MD, PhD

Cancer Network spoke with Ahmad Tarhini, MD, PhD, about the results of the phase III United States Intergroup E1609 trial, presented at ASCO 2019.

Cancer Network spoke with Ahmad Tarhini, MD, PhD, a medical oncologist with at Emory Winship Cancer Institute, about a phase III study of adjuvant ipilimumab versus high-dose interferon-a2b for treating resected high-risk melanoma. The results of the trial were presented at ASCO 2019.